Actively Recruiting
Evaluating the Safety and Effectiveness of Weekly NNC0487-0111 Injections for Adults with Overweight or Obesity and Obstructive Sleep Apnoea Not Using Positive Airway Pressure
Led by Novo Nordisk A/S · Updated on 2026-09-11
300
Participants Needed
80
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of the drug NNC0487-0111 in adults with excess body weight and moderate-to-severe obstructive sleep apnoea OSA who are not treated with positive airway pressure. This Phase 3 study randomizes participants to receive either NNC0487-0111 or a placebo to assess their ability to lose weight and improve sleep apnoea symptoms. Participants will receive weekly injections under the skin using pre-filled pen-injectors of either NNC0487-0111 or placebo. Both groups will follow a reduced-calorie diet and increase physical activity. The treatment period lasts 80 weeks, during which the effects on body weight and sleep apnoea will be monitored. During the study, participants will have regular assessments including measurements of body weight, apnoea-hypopnoea index AHI, sleepiness scales, blood pressure, cholesterol levels, blood sugar, and other health indicators. Safety will be monitored through tracking adverse events up to 84 weeks. The study aims to measure changes from baseline to week 80 to evaluate treatment impact.
CONDITIONS
Brief Title
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here